<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892238</url>
  </required_header>
  <id_info>
    <org_study_id>АААА-А18-118021590202-9</org_study_id>
    <secondary_id>АААА-А18-118021590202-9</secondary_id>
    <secondary_id>АААА-А17-117080910167-9</secondary_id>
    <nct_id>NCT04892238</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Infection Occurrence in Russia</brief_title>
  <official_title>Helicobacter Pylori Infection Occurrence in Primary Care Settings in Russia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Scientific Institution &quot;Federal Research Centre of Nutrition, Biotechnology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Moscow Clinical Scientific Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Friendship University of Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal State Budgetary Scientific Institution &quot;Federal Research Centre of Nutrition, Biotechnology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to reveal the occurrence rate of H.pylori infection in ambulatory&#xD;
      settings' patients in Russia and to compare the occurrence rates in different years in&#xD;
      treatment-naïve and previously treated subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of H.pylori infection</measure>
    <time_frame>during the procedure</time_frame>
    <description>Delta over the baseline (δ) of 13C/12C based on the results of the initial and second samples ≥4.0‰ are positive</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">70000</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Treatment-naïve</arm_group_label>
    <description>Subjects without previous experience of treatment provided for H.pylori infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment experienced</arm_group_label>
    <description>Subjects who were previously tested positive for H.pylori infection and who were treated for H.pylori infection with at least 2 antibiotics in combination with proton pump inhibitor not less than 6 weeks before the 13C-urea breath test</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>13-C urea breath test</intervention_name>
    <description>Standard urea breath test (UBT) (&quot;HELICARB&quot;, LLC &quot;ISOCARB&quot;, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.&#xD;
Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer &quot;IRIS.Doc&quot; (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was &lt;4.0‰; test results with δ ≥4.0‰ are considered positive.</description>
    <arm_group_label>Treatment-naïve</arm_group_label>
    <arm_group_label>treatment experienced</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory subjects, referred to perform urea breath test (UBT) and who gave written&#xD;
        informed consent for the use of their data for research purposes are aligible for the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  willingness to participate (based on the signed informed consent form);&#xD;
&#xD;
          -  age older than 12 y.o. (for subjects younger than 18 y.o. written informed consent of&#xD;
             a legal representative was obligatory);&#xD;
&#xD;
          -  availability of demographic data and medical history, including previous treatment for&#xD;
             H.pylori infection&#xD;
&#xD;
        For subjects of &quot;treatment-naïve&quot; group:&#xD;
&#xD;
          -  no previous treatment for H.pylori infection in the anamnesis;&#xD;
&#xD;
          -  at least 6 weeks after previous use of any antimicrobial agents for any reason;&#xD;
&#xD;
          -  at least 2 weeks' time frame free of use of proton pump inhibitors, other&#xD;
             anti-secretory agents and bismuth preparations.&#xD;
&#xD;
        For &quot;Previously treated&quot; group of subjects:&#xD;
&#xD;
          -  infection caused by H.pylori established earlier and&#xD;
&#xD;
          -  not less than 6 weeks after the end of eradication therapy with at least 2 antibiotics&#xD;
             and a proton pump inhibitor for at least 7 days, based on a patient's report&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of surgery on chest, stomach, gut (excluding appendectomy or laparoscopic&#xD;
             cholecystectomy performed more than 6 month before the enrolment);&#xD;
&#xD;
          -  advanced stage of chronic obstructive pulmonary disease,&#xD;
&#xD;
          -  allergies to citruses,&#xD;
&#xD;
          -  pregnant and breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Bordin, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow Clinical Scientific Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moscow Clinical Scientific Center</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution &quot;Federal Research Centre of Nutrition, Biotechnology</name>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal State Budgetary Scientific Institution &quot;Federal Research Centre of Nutrition, Biotechnology</investigator_affiliation>
    <investigator_full_name>Sergey Morozov</investigator_full_name>
    <investigator_title>Leading researcher</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>occurrence</keyword>
  <keyword>ambulatory settings</keyword>
  <keyword>prospective trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Depersonalised data will be available upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Upon request</ipd_time_frame>
    <ipd_access_criteria>reasonable request to the principal investigator</ipd_access_criteria>
    <ipd_url>http://ion.ru</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

